



## Clinical trial results:

### A Phase 3b, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Re-induction Therapy With Ustekinumab in Patients with Moderately to Severely Active Crohn's Disease

#### Summary

EudraCT number	2018-002629-51
Trial protocol	NL ES SE FR AT GB CZ IT
Global end of trial date	10 January 2023

#### Results information

Result version number	v1 (current)
This version publication date	21 January 2024
First version publication date	21 January 2024

#### Trial information

##### Trial identification

Sponsor protocol code	CNT01275CRD3008
-----------------------	-----------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03782376
WHO universal trial number (UTN)	-

Notes:

##### Sponsors

Sponsor organisation name	Janssen-Cilag Ltd.
Sponsor organisation address	Archimedesweg 29, Leiden, Netherlands, 2333 CM
Public contact	Clinical Registry Group, Janssen-Cilag Ltd., ClinicalTrialsEU@its.jnj.com
Scientific contact	Clinical Registry Group, Janssen-Cilag Ltd., ClinicalTrialsEU@its.jnj.com

Notes:

##### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	10 January 2023
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	10 January 2023
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The main objective of this study was to evaluate the achievement of clinical response at Week 16 following a single intravenous (IV) re-induction dose of 6 milligrams per kilogram (mg/kg) ustekinumab, compared with continuing regular subcutaneous (SC) every 8 weeks (q8w) 90 mg ustekinumab administration, in subjects with secondary loss of response (LoR) to SC q8w 90 mg ustekinumab maintenance therapy.

Protection of trial subjects:

This study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with Good Clinical Practices and applicable regulatory requirements.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	20 December 2018
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	France: 14
Country: Number of subjects enrolled	Germany: 69
Country: Number of subjects enrolled	Italy: 10
Country: Number of subjects enrolled	Netherlands: 5
Country: Number of subjects enrolled	Korea, Republic of: 11
Country: Number of subjects enrolled	Czechia: 5
Country: Number of subjects enrolled	Russian Federation: 8
Country: Number of subjects enrolled	Spain: 16
Country: Number of subjects enrolled	Sweden: 2
Country: Number of subjects enrolled	United Kingdom: 8
Country: Number of subjects enrolled	United States: 67
Worldwide total number of subjects	215
EEA total number of subjects	121

Notes:

<b>Subjects enrolled per age group</b>	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	203
From 65 to 84 years	12
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

A total of 215 subjects were enrolled, of which 159 subjects completed the study.

### Period 1

Period 1 title	Overall (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Carer, Assessor

### Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

<b>Arm title</b>	Group 1: Ustekinumab (IV Re-induction)
------------------	----------------------------------------

Arm description:

Subjects who initially responded to ustekinumab induction therapy followed by a secondary LoR to ustekinumab administered as SC injection q8w maintenance therapy received a weight-tiered based re-induction dose of ustekinumab 6 mg/kg as an intravenous IV infusion and placebo matching to ustekinumab as SC injection at Week 0. At Weeks 8 and 16, all subjects received ustekinumab 90 mg maintenance dose as SC injection. At Week 24, all subjects underwent study assessments before resuming their standard-of-care therapy at the discretion of the treating physician. Subjects were followed-up for safety up to Week 36.

Arm type	Experimental
Investigational medicinal product name	Ustekinumab
Investigational medicinal product code	
Other name	STELARA
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Subjects received IV infusion of 6 mg/kg Ustekinumab at Week 0.

Investigational medicinal product name	Ustekinumab
Investigational medicinal product code	
Other name	STELARA
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects received SC maintenance injections of 90 mg ustekinumab at Weeks 8 and 16.

Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects received SC injection of placebo (matched to Ustekinumab) at Week 0.

<b>Arm title</b>	Group 2: Ustekinumab (Continuous q8w SC Maintenance)
------------------	------------------------------------------------------

Arm description:

Subjects who initially responded to ustekinumab induction therapy followed by a secondary LoR to ustekinumab administered as SC injection q8w maintenance therapy received ustekinumab 90 mg as SC injection and placebo matching to ustekinumab as an IV infusion at Week 0. At Weeks 8 and 16, all

subjects received ustekinumab 90 mg maintenance dose as SC injection. At Week 24, all subjects underwent study assessments before resuming their standard-of-care therapy at the discretion of the treating physician. Subjects were followed-up for safety up to Week 36.

Arm type	Experimental
Investigational medicinal product name	Ustekinumab
Investigational medicinal product code	
Other name	STELARA
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects received SC maintenance injections of 90 mg ustekinumab at Weeks 0, 8, and 16.

Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Subjects received IV infusion of placebo (matched to Ustekinumab) at Week 0.

Number of subjects in period 1	Group 1: Ustekinumab (IV Re-induction)	Group 2: Ustekinumab (Continuous q8w SC Maintenance)
Started	108	107
Completed	82	77
Not completed	26	30
Adverse event, serious fatal	1	-
Consent withdrawn by subject	7	11
Unspecified	16	17
Lost to follow-up	2	2

## Baseline characteristics

### Reporting groups

Reporting group title	Group 1: Ustekinumab (IV Re-induction)
-----------------------	----------------------------------------

Reporting group description:

Subjects who initially responded to ustekinumab induction therapy followed by a secondary LoR to ustekinumab administered as SC injection q8w maintenance therapy received a weight-tiered based re-induction dose of ustekinumab 6 mg/kg as an intravenous IV infusion and placebo matching to ustekinumab as SC injection at Week 0. At Weeks 8 and 16, all subjects received ustekinumab 90 mg maintenance dose as SC injection. At Week 24, all subjects underwent study assessments before resuming their standard-of-care therapy at the discretion of the treating physician. Subjects were followed-up for safety up to Week 36.

Reporting group title	Group 2: Ustekinumab (Continuous q8w SC Maintenance)
-----------------------	------------------------------------------------------

Reporting group description:

Subjects who initially responded to ustekinumab induction therapy followed by a secondary LoR to ustekinumab administered as SC injection q8w maintenance therapy received ustekinumab 90 mg as SC injection and placebo matching to ustekinumab as an IV infusion at Week 0. At Weeks 8 and 16, all subjects received ustekinumab 90 mg maintenance dose as SC injection. At Week 24, all subjects underwent study assessments before resuming their standard-of-care therapy at the discretion of the treating physician. Subjects were followed-up for safety up to Week 36.

Reporting group values	Group 1: Ustekinumab (IV Re-induction)	Group 2: Ustekinumab (Continuous q8w SC Maintenance)	Total
Number of subjects	108	107	215
Title for AgeCategorical Units: subjects			
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	102	101	203
From 65 to 84 years	6	6	12
85 years and over	0	0	0
Title for AgeContinuous Units: years			
arithmetic mean	41.8	40	
standard deviation	± 13.63	± 13.07	-
Title for Gender Units: subjects			
Female	62	62	124
Male	46	45	91

## End points

### End points reporting groups

Reporting group title	Group 1: Ustekinumab (IV Re-induction)
Reporting group description: Subjects who initially responded to ustekinumab induction therapy followed by a secondary LoR to ustekinumab administered as SC injection q8w maintenance therapy received a weight-tiered based re-induction dose of ustekinumab 6 mg/kg as an intravenous IV infusion and placebo matching to ustekinumab as SC injection at Week 0. At Weeks 8 and 16, all subjects received ustekinumab 90 mg maintenance dose as SC injection. At Week 24, all subjects underwent study assessments before resuming their standard-of-care therapy at the discretion of the treating physician. Subjects were followed-up for safety up to Week 36.	
Reporting group title	Group 2: Ustekinumab (Continuous q8w SC Maintenance)
Reporting group description: Subjects who initially responded to ustekinumab induction therapy followed by a secondary LoR to ustekinumab administered as SC injection q8w maintenance therapy received ustekinumab 90 mg as SC injection and placebo matching to ustekinumab as an IV infusion at Week 0. At Weeks 8 and 16, all subjects received ustekinumab 90 mg maintenance dose as SC injection. At Week 24, all subjects underwent study assessments before resuming their standard-of-care therapy at the discretion of the treating physician. Subjects were followed-up for safety up to Week 36.	

### Primary: Percentage of Subjects With Clinical Response at Week 16

End point title	Percentage of Subjects With Clinical Response at Week 16
End point description: Clinical response: greater than or equal to ( $\geq$ ) 100-point reduction from baseline in Crohn's disease activity index (CDAI) score or a CDAI score $< 150$ points. CDAI is a measure of severity of illness derived as weighted sum of 8 Crohn's disease (CD)-related variables (extra-intestinal manifestations, abdominal mass, weight, hematocrit, total number of liquid stools, abdominal pain/cramping, use of antidiarrheal drug(s) and/or opiates, and general well-being). The last 4 variables were scored on diary over 7 days by subjects. CDAI score ranges from 0 to approximately 600; higher score indicates higher disease activities. Subjects with prohibited CD-related surgery, prohibited concomitant medication changes or discontinued study agent due to lack of efficacy or adverse event indicated of worsening CD prior to designated analysis timepoint were considered not in clinical response, regardless of their CDAI score. Full analysis set (FAS) included randomised subjects.	
End point type	Primary
End point timeframe: Week 16	

End point values	Group 1: Ustekinumab (IV Re- induction)	Group 2: Ustekinumab (Continuous q8w SC Maintenance)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	108	107		
Units: Percentage of subjects				
number (not applicable)	49.1	37.4		

### Statistical analyses

<b>Statistical analysis title</b>	Ustekinumab IV Vs Ustekinumab SC
Statistical analysis description: The fixed sequence testing method was used. Cochran-Mantel Haenszel (CMH)-chi-square test stratified by baseline CDAI score ( $\leq 300$ or $> 300$ ), and prior biologic failure status at baseline (yes or no).	
Comparison groups	Group 1: Ustekinumab (IV Re-induction) v Group 2: Ustekinumab (Continuous q8w SC Maintenance)
Number of subjects included in analysis	215
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.089 <sup>[1]</sup>
Method	Cochran-Mantel Haenszel-chi-square test
Parameter estimate	Difference in percentage
Point estimate	11.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.5
upper limit	24.5

Notes:

[1] - Threshold for significance was 0.05 level.

## Secondary: Percentage of Subjects With Clinical Response at Week 8

End point title	Percentage of Subjects With Clinical Response at Week 8
End point description: Clinical response was defined as a $\geq 100$ -point reduction from the baseline in CDAI score or a CDAI score $< 150$ point. The CDAI is a measure of severity of illness derived as a weighted sum of 8 different CD-related variables (extra-intestinal manifestations, abdominal mass, weight, hematocrit, total number of liquid stools, abdominal pain/cramping, use of antidiarrheal drug(s) and/or opiates, and general well-being). The last 4 variables were scored over 7 days by the subject on a diary card. In general, CDAI score ranges from 0 to approximately 600; higher score indicates higher disease activities. Subjects who had prohibited CD-related surgery, prohibited concomitant medication changes or discontinued study agent due to lack of efficacy or adverse event indicated to be of worsening CD prior to designated analysis timepoint were considered not to be in clinical response, regardless of their CDAI score. FAS included all randomised subjects.	
End point type	Secondary
End point timeframe: Week 8	

End point values	Group 1: Ustekinumab (IV Re-induction)	Group 2: Ustekinumab (Continuous q8w SC Maintenance)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	108	107		
Units: Percentage of subjects				
number (not applicable)	51.9	44.9		

## Statistical analyses



<b>Statistical analysis title</b>	Ustekinumab IV Vs Ustekinumab SC
Statistical analysis description: The fixed sequence testing method was used. CMH chi-square test (2-sided) stratified by baseline CDAI score ( $\leq 300$ or $> 300$ ), and prior biologic failure status at baseline (yes or no).	
Comparison groups	Group 1: Ustekinumab (IV Re-induction) v Group 2: Ustekinumab (Continuous q8w SC Maintenance)
Number of subjects included in analysis	215
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3 <sup>[2]</sup>
Method	CMH chi-square test (2-sided)
Parameter estimate	Difference in percentage
Point estimate	7.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6
upper limit	20.2

Notes:

[2] - Since the primary endpoint did not achieve statistical significance, all p-values for the major secondary endpoints are nominal and are not statistically significant.

### Secondary: Percentage of Subjects With Clinical Remission at Week 16

End point title	Percentage of Subjects With Clinical Remission at Week 16
End point description: Percentage of subjects with clinical remission at Week 16 were reported. Clinical remission was defined as CDAI score of <150 points. CDAI is a measure of severity of illness derived as weighted sum of 8 different CD-related variables (extra-intestinal manifestations, abdominal mass, weight, hematocrit, total number of liquid stools, abdominal pain/cramping, use of antidiarrheal drug(s) and/or opiates and general well-being). The last 4 variables were scored over 7 days by subject on diary card. In general, CDAI score ranges from 0 to approximately 600; higher score=higher disease activities. Subjects who had prohibited CD-related surgery, prohibited concomitant medication changes or discontinued study agent due to lack of efficacy or adverse event indicated to be of worsening CD prior to designated analysis timepoint were considered not to be in clinical remission, regardless of their CDAI score. FAS included all randomised subjects.	
End point type	Secondary
End point timeframe: Week 16	

End point values	Group 1: Ustekinumab (IV Re-induction)	Group 2: Ustekinumab (Continuous q8w SC Maintenance)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	108	107		
Units: Percentage of subjects				
number (not applicable)	33.3	27.1		

### Statistical analyses

<b>Statistical analysis title</b>	Ustekinumab IV Vs Ustekinumab SC
Statistical analysis description: The fixed sequence testing method was used. CMH chi-square test (2-sided) stratified by baseline CDAI score ( $\leq 300$ or $> 300$ ), and prior biologic failure status at baseline (yes or no).	
Comparison groups	Group 1: Ustekinumab (IV Re-induction) v Group 2: Ustekinumab (Continuous q8w SC Maintenance)
Number of subjects included in analysis	215
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.338 <sup>[3]</sup>
Method	CMH chi-square test (2-sided)
Parameter estimate	Difference in percentage
Point estimate	5.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6
upper limit	17.8

Notes:

[3] - Since the primary endpoint did not achieve statistical significance, all p-values for the major secondary endpoints are nominal and are not statistically significant.

### Secondary: Percentage of Subjects With Clinical Remission at Week 8

End point title	Percentage of Subjects With Clinical Remission at Week 8
End point description: Percentage of subjects with clinical remission at Week 8 were reported. Clinical remission was defined as CDAI score of <150 points. CDAI is a measure of severity of illness derived as weighted sum of 8 different CD-related variables (extra-intestinal manifestations, abdominal mass, weight, hematocrit, total number of liquid stools, abdominal pain/cramping, use of antidiarrheal drug(s) and/or opiates and general well-being). The last 4 variables were scored over 7 days by subject on diary card. In general, CDAI score ranges from 0 to approximately 600; higher score=higher disease activities. Subjects who had prohibited CD-related surgery, prohibited concomitant medication changes or discontinued study agent due to lack of efficacy or adverse event indicated to be of worsening CD prior to designated analysis timepoint were considered not to be in clinical remission, regardless of their CDAI score. FAS included all randomised subjects.	
End point type	Secondary
End point timeframe: Week 8	

End point values	Group 1: Ustekinumab (IV Re-induction)	Group 2: Ustekinumab (Continuous q8w SC Maintenance)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	108	107		
Units: Percentage of subjects				
number (not applicable)	35.2	29.0		

### Statistical analyses

<b>Statistical analysis title</b>	Ustekinumab IV Vs Ustekinumab SC
Statistical analysis description: The fixed sequence testing method was used. CMH chi-square test (2-sided) stratified by baseline CDAI score ( $\leq 300$ or $> 300$ ), and prior biologic failure status at baseline (yes or no).	
Comparison groups	Group 1: Ustekinumab (IV Re-induction) v Group 2: Ustekinumab (Continuous q8w SC Maintenance)
Number of subjects included in analysis	215
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.314 <sup>[4]</sup>
Method	CMH chi-square test (2-sided)
Parameter estimate	Difference in percentage
Point estimate	6.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.8
upper limit	18.6

Notes:

[4] - Since the primary endpoint did not achieve statistical significance, all p-values for the major secondary endpoints are nominal and are not statistically significant.

### **Secondary: Percentage of Subjects with Normalisation of C-reactive Protein (CRP) and/or Normalisation of Fecal Calprotectin (fCal) Concentration at Week 16**

End point title	Percentage of Subjects with Normalisation of C-reactive Protein (CRP) and/or Normalisation of Fecal Calprotectin (fCal) Concentration at Week 16
-----------------	--------------------------------------------------------------------------------------------------------------------------------------------------

End point description:

Percentage of subjects with normalisation at Week 16, among subjects with elevated CRP and/or fCal at baseline were reported. Subjects were considered normalised if at least one biomarker (fCal or CRP) was normalised. Normalised CRP=CRP value less than or equal to ( $\leq$ ) 3 milligrams per liter(mg/L). Normalised fCal concentrations was defined as  $\leq 250$  micrograms per gram(mcg/g). When either CRP or fCal value was abnormal at baseline and value of same parameter normalises at analysis time, subjects were considered normalised at designated analysis timepoint. Subjects with prohibited CD-related surgery, prohibited concomitant medication changes, or discontinued drug due to lack of efficacy or adverse event indicated of worsening CD prior to analysis time are considered not normalised. Subjects with insufficient data at analysis timepoint had last value carried forward. FAS included all randomised subjects with either elevated CRP and/or elevated fCal at baseline.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 16

<b>End point values</b>	Group 1: Ustekinumab (IV Re-induction)	Group 2: Ustekinumab (Continuous q8w SC Maintenance)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	93	94		
Units: Percentage of subjects				
number (not applicable)	33.3	14.9		

## Statistical analyses

<b>Statistical analysis title</b>	Ustekinumab IV Vs Ustekinumab SC
Statistical analysis description: The fixed sequence testing method was used. CMH chi-square test (2-sided) stratified by baseline CDAI score ( $\leq 300$ or $> 300$ ), and prior biologic failure status at baseline (yes or no).	
Comparison groups	Group 1: Ustekinumab (IV Re-induction) v Group 2: Ustekinumab (Continuous q8w SC Maintenance)
Number of subjects included in analysis	187
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.004 <sup>[5]</sup>
Method	CMH chi-square test (2-sided)
Parameter estimate	Difference in percentage
Point estimate	18.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	6.8
upper limit	30.2

Notes:

[5] - Since the primary endpoint did not achieve statistical significance, all p-values for the major secondary endpoints are nominal and are not statistically significant.

## Secondary: Percentage of Subjects With Clinical Response at Week 24

End point title	Percentage of Subjects With Clinical Response at Week 24
End point description: Clinical response was defined as a $\geq 100$ -point reduction from the baseline in CDAI score or a CDAI score $< 150$ point. The CDAI is a measure of severity of illness derived as a weighted sum of 8 different Crohn's disease-related variables (extra-intestinal manifestations, abdominal mass, weight, hematocrit, total number of liquid stools, abdominal pain/cramping, use of antidiarrheal drug(s) and/or opiates, and general well-being). The last 4 variables were scored over 7 days by the subject on a diary card. In general, CDAI score ranges from 0 to approximately 600; higher score indicates higher disease activities. Subjects who had prohibited CD-related surgery, prohibited concomitant medication changes or discontinued study agent due to lack of efficacy or adverse event indicated to be of worsening CD prior to designated analysis timepoint were considered not to be in clinical response, regardless of their CDAI score. FAS included all randomised subjects.	
End point type	Secondary
End point timeframe: Week 24	

End point values	Group 1: Ustekinumab (IV Re- induction)	Group 2: Ustekinumab (Continuous q8w SC Maintenance)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	108	107		
Units: Percentage of subjects				
number (not applicable)	47.2	39.3		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of Subjects With Clinical Remission at Week 24

End point title	Percentage of Subjects With Clinical Remission at Week 24
End point description:	
Percentage of subjects with clinical remission at Week 24 were reported. Clinical remission was defined as CDAI score of <150 points. CDAI is a measure of severity of illness derived as weighted sum of 8 different CD-related variables (extra-intestinal manifestations, abdominal mass, weight, hematocrit, total number of liquid stools, abdominal pain/cramping, use of antidiarrheal drug(s) and/or opiates and general well-being). The last 4 variables were scored over 7 days by subject on diary card. In general, CDAI score ranges from 0 to approximately 600; higher score=higher disease activities. Subjects who had prohibited CD-related surgery, prohibited concomitant medication changes or discontinued study agent due to lack of efficacy or adverse event indicated to be of worsening CD prior to designated analysis timepoint were considered not to be in clinical remission, regardless of their CDAI score. FAS included all randomised subjects.	
End point type	Secondary
End point timeframe:	
Week 24	

End point values	Group 1: Ustekinumab (IV Re- induction)	Group 2: Ustekinumab (Continuous q8w SC Maintenance)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	108	107		
Units: Percentage of subjects				
number (not applicable)	37.0	27.1		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of Subjects with Normalisation of C-reactive Protein (CRP) and/or Normalisation of Fecal Calprotectin (fCal) Concentration at Week 24

End point title	Percentage of Subjects with Normalisation of C-reactive Protein (CRP) and/or Normalisation of Fecal Calprotectin (fCal)
-----------------	-------------------------------------------------------------------------------------------------------------------------

## End point description:

Percentage of subjects with normalisation at Week 24, among subjects with elevated CRP and/or fCal at baseline were reported. Subjects were considered normalised if at least one biomarker (fCal or CRP) was normalised. Normalised CRP=CRP value less than or equal to ( $\leq$ ) 3 milligrams per liter(mg/L). Normalised fCal concentrations was defined as  $\leq$ 250 micrograms per gram(mcg/g). When either CRP or fCal value was abnormal at baseline and value of same parameter normalises at analysis time, subjects were considered normalised at designated analysis timepoint. Subjects with prohibited CD-related surgery, prohibited concomitant medication changes, or discontinued drug due to lack of efficacy or adverse event indicated of worsening CD prior to analysis time are considered not normalised. Subjects with insufficient data at analysis timepoint had last value carried forward. FAS included all randomised subjects with either elevated CRP and/or elevated fCal at baseline.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 24

End point values	Group 1: Ustekinumab (IV Re- induction)	Group 2: Ustekinumab (Continuous q8w SC Maintenance)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	93	94		
Units: Percentage of subjects				
number (not applicable)	26.9	21.3		

## Statistical analyses

No statistical analyses for this end point

**Secondary: Percentage of Subjects with Treatment-emergent Adverse Events (TEAEs)**

End point title	Percentage of Subjects with Treatment-emergent Adverse Events (TEAEs)
-----------------	-----------------------------------------------------------------------

## End point description:

An adverse event was any untoward medical occurrence in a clinical study subject administered a medicinal (investigational or non-investigational) product. An adverse event does not necessarily have a causal relationship with the treatment. TEAEs were adverse events with onset during the intervention phase or that were a consequence of a pre-existing condition that had worsened since baseline. Any AE occurring at or after the initial administration of study agent through the end of the trial was considered to be treatment emergent. In this endpoint, TEAEs including all AEs irrespective of being serious or non-serious AE are reported. Safety analysis set included all randomised subjects who received at least 1 administration of study agent. Subjects were analysed according to the actual treatment received.

End point type	Secondary
----------------	-----------

End point timeframe:

From baseline (Week 0) up to Week 36

End point values	Group 1: Ustekinumab (IV Re- induction)	Group 2: Ustekinumab (Continuous q8w SC Maintenance)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	108	107		
Units: Percentage of subjects				
number (not applicable)	70.4	72.9		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of Subjects with Treatment-emergent Serious Adverse Events (TESAEs)

End point title	Percentage of Subjects with Treatment-emergent Serious Adverse Events (TESAEs)
-----------------	--------------------------------------------------------------------------------

End point description:

A serious adverse event (SAE) was an adverse event resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalisation; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; a suspected transmission of any infectious agent via a medicinal product; medically important. TESAEs were adverse events with onset during the intervention phase or that are a consequence of a pre-existing condition that had worsened since baseline. Any AE occurring at or after the initial administration of study agent through the end of the trial was considered to be treatment emergent. Safety analysis set included all randomised subjects who received at least 1 administration of study agent. Subjects were analysed according to the actual treatment received.

End point type	Secondary
----------------	-----------

End point timeframe:

From baseline (Week 0) up to Week 36

End point values	Group 1: Ustekinumab (IV Re- induction)	Group 2: Ustekinumab (Continuous q8w SC Maintenance)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	108	107		
Units: Percentage of subjects				
number (not applicable)	8.3	12.1		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of Subjects with Treatment-emergent Serious Infections

End point title	Percentage of Subjects with Treatment-emergent Serious Infections
-----------------	-------------------------------------------------------------------

**End point description:**

Percentage of subjects with treatment-emergent serious infections was reported. Any infection occurring at or after the initial administration of study agent through the end of the trial was considered to be treatment emergent. safety analysis set included all randomised subjects who received at least 1 administration of study agent. Subjects were analysed according to the actual treatment received.

End point type	Secondary
----------------	-----------

**End point timeframe:**

From baseline (Week 0) up to Week 36

<b>End point values</b>	Group 1: Ustekinumab (IV Re- induction)	Group 2: Ustekinumab (Continuous q8w SC Maintenance)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	108	107		
Units: Percentage of subjects				
number (not applicable)	1.9	1.9		

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Change from Baseline in Clinical Laboratory Values for Hematology (Hemoglobin) and Chemistry (Albumin, Total Protein)**

End point title	Change from Baseline in Clinical Laboratory Values for Hematology (Hemoglobin) and Chemistry (Albumin, Total Protein)
-----------------	-----------------------------------------------------------------------------------------------------------------------

**End point description:**

Change from baseline in clinical laboratory values for hematology (hemoglobin) and chemistry (albumin, total protein) was reported. Safety analysis set included all randomised subjects who received at least 1 administration of study agent. Subjects were analysed according to the actual treatment received. Here, 'N' (number of subjects analysed) signifies subjects who were evaluable for this endpoint and 'n' signifies subjects who were evaluated at specified timepoints for specified parameters.

End point type	Secondary
----------------	-----------

**End point timeframe:**

Baseline, Weeks 8, 16, 24

<b>End point values</b>	Group 1: Ustekinumab (IV Re- induction)	Group 2: Ustekinumab (Continuous q8w SC Maintenance)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	103	98		
Units: Grams per liter (g/L)				
arithmetic mean (standard deviation)				
Week 8: Hematology (Hemoglobin) (n=103, 92)	2.893 (± 9.5568)	-0.185 (± 7.8669)		



Week 16: Hematology (Hemoglobin) (n=94,85)	3.245 (± 10.4621)	0.835 (± 10.4652)		
Week 24: Hematology (Hemoglobin) (n=74,75)	3.203 (± 11.2408)	-0.400 (± 11.2610)		
Week 8: Chemistry (Albumin) (n=102,98)	0.765 (± 2.9456)	0.286 (± 2.6671)		
Week 16: Chemistry (Albumin) (n=97,92)	0.567 (± 3.0649)	0.554 (± 3.3753)		
Week 24: Chemistry (Albumin) (n=81,77)	0.741 (± 2.9613)	0.221 (± 3.1690)		
Week 8: Chemistry (Total protein) (n=102,98)	0.588 (± 4.6806)	0.265 (± 4.3803)		
Week 16: Chemistry (Total protein) (n=97,92)	0.340 (± 5.2418)	0.783 (± 4.7690)		
Week 24: Chemistry (Total protein) (n=81,78)	0.605 (± 4.4150)	0.333 (± 5.4954)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Subjects with Treatment-emergent Infections

End point title	Percentage of Subjects with Treatment-emergent Infections
End point description:	
Percentage of subjects with treatment-emergent infections were reported. Any infection occurring at or after the initial administration of study agent through the end of the trial was considered to be treatment emergent. Safety analysis set included all randomised subjects who received at least 1 administration of study agent. Subjects were analysed according to the actual treatment received.	
End point type	Secondary
End point timeframe:	
From baseline (Week 0) up to Week 36	

End point values	Group 1: Ustekinumab (IV Re- induction)	Group 2: Ustekinumab (Continuous q8w SC Maintenance)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	108	107		
Units: Percentage of subjects				
number (not applicable)	33.3	29.9		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline in Clinical Laboratory Values for Hematology (Hematocrit)

End point title	Change from Baseline in Clinical Laboratory Values for
-----------------	--------------------------------------------------------

## End point description:

Change from baseline in clinical laboratory values for hematology (hematocrit) was reported. Safety analysis set included all randomised subjects who received at least 1 administration of study agent. Subjects were analysed according to the actual treatment received. Here, 'N' (number of subjects analysed) signifies subjects who were evaluable for this endpoint and 'n' signifies subjects who were evaluated at specified timepoints

End point type	Secondary
----------------	-----------

## End point timeframe:

Baseline, Weeks 8, 16, 24

End point values	Group 1: Ustekinumab (IV Re- induction)	Group 2: Ustekinumab (Continuous q8w SC Maintenance)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	101	88		
Units: Percentage of red blood cells				
arithmetic mean (standard deviation)				
Week 8 (n=101,88)	0.009 (± 0.0313)	-0.001 (± 0.277)		
Week 16 (n=90,83)	0.010 (± 0.0306)	0.001 (± 0.0356)		
Week 24 (n=74,71)	0.009 (± 0.0358)	0.001 (± 0.0349)		

## Statistical analyses

No statistical analyses for this end point

**Secondary: Change from Baseline in Clinical Laboratory values for Hematology (Total White Blood Cell [WBC], Neutrophils, Absolute Lymphocyte, Eosinophils, Platelets)**

End point title	Change from Baseline in Clinical Laboratory values for Hematology (Total White Blood Cell [WBC], Neutrophils, Absolute Lymphocyte, Eosinophils, Platelets)
-----------------	------------------------------------------------------------------------------------------------------------------------------------------------------------

## End point description:

Change from baseline in clinical laboratory values for hematology (total WBC, neutrophils, absolute lymphocyte, eosinophils, platelets) was reported. Safety analysis set included all randomised subjects who received at least 1 administration of study agent. Subjects were analysed according to the actual treatment received. Here, 'N' (number of subjects analysed) signifies subjects who were evaluable for this endpoint and 'n' signifies subjects who were evaluated at specified timepoints for specific parameters

End point type	Secondary
----------------	-----------

## End point timeframe:

Baseline, Weeks 8, 16, 24

End point values	Group 1: Ustekinumab (IV Re- induction)	Group 2: Ustekinumab (Continuous q8w SC Maintenance)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	103	92		
Units: 10 <sup>9</sup> cells/L				
arithmetic mean (standard deviation)				
Week 8: Total WBC (n=103,92)	-0.386 (± 1.8358)	-0.272 (± 1.7301)		
Week 16: Total WBC (n=94,85)	-0.329 (± 2.2700)	-0.124 (± 2.1404)		
Week 24: Total WBC (n=74,75)	-0.149 (± 2.2347)	0.104 (± 1.6612)		
Week 8: Neutrophils (n=103, 92)	-0.235 (± 1.7610)	-0.241 (± 1.6154)		
Week 16: Neutrophils (n=94,85)	-0.195 (± 2.0172)	-0.053 (± 2.1811)		
Week 24: Neutrophils (n=74,75)	-0.038 (± 2.2944)	0.133 (± 1.4312)		
Week 8: Absolute Lymphocytes (n=103,92)	-0.101 (± 0.4962)	-0.020 (± 0.3415)		
Week 16: Absolute Lymphocytes (n=94,85)	-0.088 (± 0.5690)	-0.052 (± 0.3997)		
Week 24: Absolute Lymphocytes (n=74,75)	-0.088 (± 0.6599)	-0.021 (± 0.3960)		
Week 8: Eosinophils (n=103,92)	-0.009 (± 0.0876)	-0.004 (± 0.1153)		
Week 16: Eosinophils (n=94,85)	-0.014 (± 0.1176)	-0.013 (± 0.1330)		
Week 24: Eosinophils (n=74,75)	-0.001 (± 0.0912)	-0.008 (± 0.1136)		
Week 8: Platelets (n=103,92)	-13.65 (± 56.553)	-0.67 (± 51.591)		
Week 16: Platelets (n=93,85)	-13.28 (± 60.105)	4.53 (± 60.785)		
Week 24: Platelets (n=73,73)	-10.89 (± 62.671)	-0.53 (± 56.624)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline in Clinical Laboratory values for Chemistry (Alkaline Phosphatase, Alanine Transaminase [ALT], Aspartate Transaminase [AST])

End point title	Change from Baseline in Clinical Laboratory values for Chemistry (Alkaline Phosphatase, Alanine Transaminase [ALT], Aspartate Transaminase [AST])
-----------------	---------------------------------------------------------------------------------------------------------------------------------------------------

End point description:

Change from baseline in clinical laboratory values for chemistry (alkaline, ALT, AST) was reported. Safety analysis set included all randomised subjects who received at least 1 administration of study agent. Subjects were analysed according to the actual treatment received. Here, 'N' (number of subjects analysed) signifies subjects who were evaluable for this endpoint and 'n' signifies subjects who were evaluated at specified timepoints for specified parameters.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Weeks 8, 16, 24

End point values	Group 1: Ustekinumab (IV Re- induction)	Group 2: Ustekinumab (Continuous q8w SC Maintenance)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	102	98		
Units: Units per Liter (U/L)				
arithmetic mean (standard deviation)				
Week 8: Alkaline Phosphatase (n=102,98)	-1.343 (± 10.7404)	-0.582 (± 10.3565)		
Week 16: Alkaline Phosphatase (n=97,91)	-0.072 (± 12.9488)	0.923 (± 11.5154)		
Week 24: Alkaline Phosphatase (n=81,77)	-0.296 (± 14.2649)	0.078 (± 16.1594)		
Week 8: ALT (n=101,97)	-0.347 (± 9.3642)	-0.412 (± 7.9001)		
Week 16: ALT (n=95,89)	-0.811 (± 8.3898)	-0.101 (± 9.9750)		
Week 24: ALT (n=80,76)	0.463 (± 10.1470)	2.224 (± 15.5979)		
Week 8: AST (n=101,97)	-0.525 (± 12.0147)	0.144 (± 4.8584)		
Week 16: AST (n=96,92)	-0.208 (± 12.6366)	0.163 (± 5.4557)		
Week 24: AST (n=81,77)	0.741 (± 5.6718)	1.519 (± 7.3047)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline in Clinical Laboratory values for Chemistry (Total Bilirubin, Direct Bilirubin, Creatinine)

End point title	Change from Baseline in Clinical Laboratory values for Chemistry (Total Bilirubin, Direct Bilirubin, Creatinine)
End point description: Change from baseline in clinical laboratory values for chemistry (total bilirubin, direct bilirubin, creatinine) was reported. Safety analysis set included all randomised subjects who received at least 1 administration of study agent. Subjects were analysed according to the actual treatment received. Here, 'N' (number of subjects analysed) signifies subjects who were evaluable for this endpoint and 'n' signifies subjects who were evaluated at specified timepoints for specified parameters.	
End point type	Secondary
End point timeframe: Baseline, Weeks 8, 16, 24	

End point values	Group 1: Ustekinumab (IV Re- induction)	Group 2: Ustekinumab (Continuous q8w SC Maintenance)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	102	98		
Units: micromole per liter (mcmol/L)				
arithmetic mean (standard deviation)				
Week 8: Total Bilirubin (n=101,97)	0.639 (± 2.5303)	-0.131 (± 2.9617)		
Week 16: Total Bilirubin (n=97,92)	1.476 (± 3.4135)	0.555 (± 3.6679)		
Week 24: Total Bilirubin (n=81,77)	0.687 (± 3.0396)	0.254 (± 3.1664)		
Week 8: Direct Bilirubin (n=100,97)	0.086 (± 0.5495)	-0.010 (± 0.5998)		
Week 16: Direct Bilirubin (n=92,90)	0.154 (± 0.6910)	0.071 (± 0.7628)		
Week 24: Direct Bilirubin (n=80,76)	0.109 (± 0.5393)	0.009 (± 0.7612)		
Week 8: Creatinine (n=102,98)	-0.446 (± 8.9118)	-0.308 (± 9.6489)		
Week 16: Creatinine (n=97,92)	0.624 (± 9.7987)	1.117 (± 9.0316)		
Week 24: Creatinine (n=81,77)	1.717 (± 9.5267)	0.336 (± 8.4020)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline in Clinical Laboratory Values for Chemistry (Sodium, Potassium, Chloride, Blood Urea Nitrogen [BUN]/urea, Calcium, Phosphate)

End point title	Change from Baseline in Clinical Laboratory Values for Chemistry (Sodium, Potassium, Chloride, Blood Urea Nitrogen [BUN]/urea, Calcium, Phosphate)
-----------------	----------------------------------------------------------------------------------------------------------------------------------------------------

End point description:

Change from baseline in clinical laboratory values for chemistry (sodium, potassium, chloride, BUN/urea, calcium, phosphate) was reported. Safety analysis set included all randomised subjects who received at least 1 administration of study agent. Subjects were analysed according to the actual treatment received. Here, 'N' (number of subjects analysed) signifies subjects who were evaluable for this endpoint and 'n' signifies subjects who were evaluated at specified timepoints for specified parameters.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Weeks 8, 16, 24

End point values	Group 1: Ustekinumab (IV Re- induction)	Group 2: Ustekinumab (Continuous q8w SC Maintenance)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	102	98		
Units: millimoles per liter (mmol/L)				
arithmetic mean (standard deviation)				
Sodium: Week 8 (n=102,98)	0.108 (± 2.5714)	-0.061 (± 2.2375)		
Sodium: Week 16 (n=97,92)	-0.165 (± 2.2299)	0.011 (± 2.3370)		
Sodium: Week 24 (n=81,77)	0.235 (± 2.2928)	-0.117 (± 2.0454)		
Potassium: Week 8 (n=101,98)	0.126 (± 0.3596)	0.050 (± 0.3269)		
Potassium: Week 16 (n=97,92)	0.105 (± 0.3745)	-0.002 (± 0.3933)		
Potassium: Week 24 (n=81,77)	0.067 (± 0.3732)	0.001 (± 0.3185)		
Chloride: Week 8 (n=102,98)	0.078 (± 2.9136)	-0.520 (± 2.4714)		
Chloride: Week 16 (n=97,92)	-0.299 (± 2.4798)	-0.489 (± 2.5398)		
Chloride: Week 24 (n=81,77)	0.160 (± 2.4107)	-0.481 (± 2.2160)		
BUN/urea: Week 8 (n=102,98)	0.279 (± 1.0050)	0.248 (± 1.0710)		
BUN/urea: Week 16 (n=97,92)	0.204 (± 1.2812)	0.029 (± 1.2841)		
BUN/urea: Week 24 (n=81,77)	0.304 (± 1.2031)	0.179 (± 1.0629)		
Calcium: Week 8 (n=102,98)	0.022 (± 0.0967)	0.013 (± 0.0968)		
Calcium: Week 16 (n=97,92)	0.007 (± 0.1010)	0.007 (± 0.1098)		
Calcium: Week 24 (n=81,77)	0.008 (± 0.1101)	0.004 (± 0.1109)		
Phosphate: Week 8 (n=102,98)	0.005 (± 0.2015)	0.046 (± 0.2024)		
Phosphate: Week 16 (n=97,92)	0.006 (± 0.1946)	0.026 (± 0.1905)		
Phosphate: Week 24 (n=81,77)	0.018 (± 0.1612)	0.021 (± 0.1938)		

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

From baseline (Week 0) up to Week 36

Adverse event reporting additional description:

Safety analysis set included all randomised subjects who received at least 1 administration of study agent. Subjectss were analysed according to the actual treatment received.

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	23.1
--------------------	------

### Reporting groups

Reporting group title	Group 2: Ustekinumab (Continuous q8w SC maintenance)
-----------------------	------------------------------------------------------

Reporting group description:

Subjects who initially responded to ustekinumab induction therapy followed by a secondary LoR to ustekinumab administered as SC injection q8w maintenance therapy received ustekinumab 90 mg as SC injection and placebo matching to ustekinumab as an IV infjusion at Week 0. At Weeks 8 and 16, all subjects received ustekinumab 90 mg maintenance dose as SC injection. At Week 24, all subjects underwent study assessments before resuming their standard-of-care therapy at the discretion of the treating physician. Subjects were followed-up for safety up to Week 36.

Reporting group title	Group 1: Ustekinumab (IV re-induction)
-----------------------	----------------------------------------

Reporting group description:

Subjects who initially responded to ustekinumab induction therapy followed by a secondary loss of response (LoR) to ustekinumab administered as subcutaneous (SC) injection every 8 weeks (q8w) maintenance therapy received a weight-tiered based re-induction dose of ustekinumab 6 milligrams per kilogram (mg/kg) as an intravenous (IV) infusion and placebo matching to ustekinumab as SC injection at Week 0. At Weeks 8 and 16, all subjects received ustekinumab 90 mg maintenance dose as SC injection. At Week 24, all subjects underwent study assessments before resuming their standard-of-care therapy at the discretion of the treating physician. Subjects were followed-up for safety up to Week 36.

Serious adverse events	Group 2: Ustekinumab (Continuous q8w SC maintenance)	Group 1: Ustekinumab (IV re- induction)	
Total subjects affected by serious adverse events			
subjects affected / exposed	13 / 107 (12.15%)	9 / 108 (8.33%)	
number of deaths (all causes)	0	1	
number of deaths resulting from adverse events	0	1	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Malignant Melanoma			
subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Acute Myocardial Infarction			

subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Atrial Fibrillation			
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pregnancy, puerperium and perinatal conditions			
Abortion Spontaneous			
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal Pain			
subjects affected / exposed	3 / 107 (2.80%)	0 / 108 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Crohn's Disease			
subjects affected / exposed	4 / 107 (3.74%)	1 / 108 (0.93%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ileal Stenosis			
subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal Obstruction			
subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small Intestinal Obstruction			
subjects affected / exposed	1 / 107 (0.93%)	1 / 108 (0.93%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	



Small Intestinal Stenosis			
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Calculus Urinary			
subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal Atrophy			
subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephrolithiasis			
subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urethral Stenosis			
subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Abdominal Abscess			
subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal Abscess			
subjects affected / exposed	1 / 107 (0.93%)	1 / 108 (0.93%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tooth Abscess			
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Urinary Tract Infection			
subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Diabetes Mellitus			
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 0 %

<b>Non-serious adverse events</b>	Group 2: Ustekinumab (Continuous q8w SC maintenance)	Group 1: Ustekinumab (IV re- induction)	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	77 / 107 (71.96%)	73 / 108 (67.59%)	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Pituitary Tumour Benign			
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)	
occurrences (all)	0	1	
Vascular disorders			
Superficial Vein Thrombosis			
subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)	
occurrences (all)	1	0	
Deep Vein Thrombosis			
subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)	
occurrences (all)	1	0	
Hypertension			
subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)	
occurrences (all)	1	0	
Pregnancy, puerperium and perinatal conditions			
Pregnancy			
subjects affected / exposed	0 / 107 (0.00%)	2 / 108 (1.85%)	
occurrences (all)	0	2	
General disorders and administration site conditions			

Asthenia			
subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)	
occurrences (all)	1	0	
Chills			
subjects affected / exposed	2 / 107 (1.87%)	0 / 108 (0.00%)	
occurrences (all)	2	0	
Fatigue			
subjects affected / exposed	3 / 107 (2.80%)	0 / 108 (0.00%)	
occurrences (all)	3	0	
Influenza Like Illness			
subjects affected / exposed	0 / 107 (0.00%)	2 / 108 (1.85%)	
occurrences (all)	0	2	
Injection Site Erythema			
subjects affected / exposed	1 / 107 (0.93%)	1 / 108 (0.93%)	
occurrences (all)	2	1	
Injection Site Mass			
subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)	
occurrences (all)	1	0	
Pyrexia			
subjects affected / exposed	4 / 107 (3.74%)	2 / 108 (1.85%)	
occurrences (all)	6	2	
Immune system disorders			
Seasonal Allergy			
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)	
occurrences (all)	0	1	
Reproductive system and breast disorders			
Cystocele			
subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)	
occurrences (all)	1	0	
Heavy Menstrual Bleeding			
subjects affected / exposed	0 / 107 (0.00%)	2 / 108 (1.85%)	
occurrences (all)	0	2	
Pelvic Fluid Collection			
subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)	
occurrences (all)	1	0	
Scrotal Dermatitis			

subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)	
occurrences (all)	1	0	
Female Genital Tract Fistula			
subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)	
occurrences (all)	1	0	
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	1 / 107 (0.93%)	1 / 108 (0.93%)	
occurrences (all)	1	1	
Cough			
subjects affected / exposed	6 / 107 (5.61%)	1 / 108 (0.93%)	
occurrences (all)	6	1	
Dyspnoea			
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)	
occurrences (all)	0	1	
Dyspnoea Exertional			
subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)	
occurrences (all)	1	0	
Epistaxis			
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)	
occurrences (all)	0	2	
Nasal Congestion			
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)	
occurrences (all)	0	1	
Oropharyngeal Pain			
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)	
occurrences (all)	0	1	
Productive Cough			
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)	
occurrences (all)	0	1	
Rhinitis Allergic			
subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)	
occurrences (all)	1	0	
Rhinorrhoea			

subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)	
occurrences (all)	1	0	
Tonsillar Disorder			
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)	
occurrences (all)	0	1	
Psychiatric disorders			
Affective Disorder			
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)	
occurrences (all)	0	1	
Conversion Disorder			
subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)	
occurrences (all)	1	0	
Depression			
subjects affected / exposed	1 / 107 (0.93%)	2 / 108 (1.85%)	
occurrences (all)	1	2	
Insomnia			
subjects affected / exposed	0 / 107 (0.00%)	2 / 108 (1.85%)	
occurrences (all)	0	2	
Restlessness			
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)	
occurrences (all)	0	1	
Investigations			
Aspartate Aminotransferase Increased			
subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)	
occurrences (all)	1	0	
Blood Alkaline Phosphatase Increased			
subjects affected / exposed	2 / 107 (1.87%)	0 / 108 (0.00%)	
occurrences (all)	2	0	
Blood Creatinine Increased			
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)	
occurrences (all)	0	1	
Blood Magnesium Decreased			
subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)	
occurrences (all)	1	0	
C-Reactive Protein Increased			

subjects affected / exposed	2 / 107 (1.87%)	0 / 108 (0.00%)	
occurrences (all)	2	0	
Gamma-Glutamyltransferase Increased			
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)	
occurrences (all)	0	1	
Sars-Cov-2 Test Positive			
subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)	
occurrences (all)	1	0	
Vitamin D Decreased			
subjects affected / exposed	1 / 107 (0.93%)	1 / 108 (0.93%)	
occurrences (all)	1	1	
Weight Increased			
subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)	
occurrences (all)	1	0	
Injury, poisoning and procedural complications			
Foot Fracture			
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)	
occurrences (all)	0	1	
Infusion Related Reaction			
subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)	
occurrences (all)	1	0	
Injection Related Reaction			
subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)	
occurrences (all)	1	0	
Ligament Rupture			
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)	
occurrences (all)	0	1	
Procedural Pain			
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)	
occurrences (all)	0	1	
Skin Laceration			
subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)	
occurrences (all)	1	0	
Spinal Compression Fracture			

subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)	
occurrences (all)	1	0	
Thermal Burn			
subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)	
occurrences (all)	1	0	
Vaccination Complication			
subjects affected / exposed	1 / 107 (0.93%)	1 / 108 (0.93%)	
occurrences (all)	1	1	
Tendon Rupture			
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)	
occurrences (all)	0	1	
Cardiac disorders			
Atrial Fibrillation			
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)	
occurrences (all)	0	1	
Nervous system disorders			
Carotid Arteriosclerosis			
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)	
occurrences (all)	0	1	
Dizziness			
subjects affected / exposed	0 / 107 (0.00%)	2 / 108 (1.85%)	
occurrences (all)	0	2	
Dizziness Postural			
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)	
occurrences (all)	0	1	
Headache			
subjects affected / exposed	5 / 107 (4.67%)	8 / 108 (7.41%)	
occurrences (all)	7	15	
Migraine			
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)	
occurrences (all)	0	1	
Ophthalmic Migraine			
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)	
occurrences (all)	0	1	
Blood and lymphatic system disorders			

Anaemia subjects affected / exposed occurrences (all)	2 / 107 (1.87%) 2	3 / 108 (2.78%) 3	
Iron Deficiency Anaemia subjects affected / exposed occurrences (all)	2 / 107 (1.87%) 2	1 / 108 (0.93%) 1	
Lymphopenia subjects affected / exposed occurrences (all)	0 / 107 (0.00%) 0	1 / 108 (0.93%) 1	
Neutropenia subjects affected / exposed occurrences (all)	1 / 107 (0.93%) 2	0 / 108 (0.00%) 0	
Ear and labyrinth disorders Ear Pain subjects affected / exposed occurrences (all)	0 / 107 (0.00%) 0	1 / 108 (0.93%) 1	
Vertigo subjects affected / exposed occurrences (all)	0 / 107 (0.00%) 0	1 / 108 (0.93%) 1	
Tinnitus subjects affected / exposed occurrences (all)	0 / 107 (0.00%) 0	1 / 108 (0.93%) 1	
Eye disorders Eye Irritation subjects affected / exposed occurrences (all)	0 / 107 (0.00%) 0	1 / 108 (0.93%) 1	
Photophobia subjects affected / exposed occurrences (all)	1 / 107 (0.93%) 1	0 / 108 (0.00%) 0	
Uveitis subjects affected / exposed occurrences (all)	0 / 107 (0.00%) 0	1 / 108 (0.93%) 1	
Gastrointestinal disorders Abdominal Discomfort subjects affected / exposed occurrences (all)	1 / 107 (0.93%) 1	2 / 108 (1.85%) 2	
Abdominal Pain			



subjects affected / exposed	3 / 107 (2.80%)	5 / 108 (4.63%)
occurrences (all)	3	6
Abdominal Mass		
subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)
occurrences (all)	1	0
Abdominal Distension		
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)
occurrences (all)	0	1
Food Poisoning		
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)
occurrences (all)	0	1
Faecaloma		
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)
occurrences (all)	0	1
Eosinophilic Oesophagitis		
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)
occurrences (all)	0	1
Dyspepsia		
subjects affected / exposed	0 / 107 (0.00%)	2 / 108 (1.85%)
occurrences (all)	0	2
Diarrhoea		
subjects affected / exposed	2 / 107 (1.87%)	0 / 108 (0.00%)
occurrences (all)	2	0
Crohn's Disease		
subjects affected / exposed	29 / 107 (27.10%)	23 / 108 (21.30%)
occurrences (all)	31	23
Constipation		
subjects affected / exposed	2 / 107 (1.87%)	0 / 108 (0.00%)
occurrences (all)	3	0
Anal Skin Tags		
subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)
occurrences (all)	1	0
Anal Fistula		
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)
occurrences (all)	0	1
Anal Fissure		

subjects affected / exposed	4 / 107 (3.74%)	0 / 108 (0.00%)
occurrences (all)	4	0
Anal Eczema		
subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)
occurrences (all)	1	0
Abdominal Tenderness		
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)
occurrences (all)	0	1
Abdominal Pain Upper		
subjects affected / exposed	2 / 107 (1.87%)	2 / 108 (1.85%)
occurrences (all)	2	2
Abdominal Pain Lower		
subjects affected / exposed	2 / 107 (1.87%)	0 / 108 (0.00%)
occurrences (all)	2	0
Gastrointestinal Inflammation		
subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)
occurrences (all)	1	0
Large Intestine Polyp		
subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)
occurrences (all)	1	0
Haemorrhoids		
subjects affected / exposed	0 / 107 (0.00%)	2 / 108 (1.85%)
occurrences (all)	0	2
Haematochezia		
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)
occurrences (all)	0	1
Gastrooesophageal Reflux Disease		
subjects affected / exposed	1 / 107 (0.93%)	2 / 108 (1.85%)
occurrences (all)	1	2
Nausea		
subjects affected / exposed	4 / 107 (3.74%)	1 / 108 (0.93%)
occurrences (all)	4	1
Rectal Haemorrhage		
subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)
occurrences (all)	1	0
Stomatitis		

subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)	
occurrences (all)	1	0	
Subileus			
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)	
occurrences (all)	0	1	
Toothache			
subjects affected / exposed	1 / 107 (0.93%)	1 / 108 (0.93%)	
occurrences (all)	1	1	
Vomiting			
subjects affected / exposed	2 / 107 (1.87%)	2 / 108 (1.85%)	
occurrences (all)	2	2	
Proctalgia			
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)	
occurrences (all)	0	1	
Hepatobiliary disorders			
Cholecystitis			
subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)	
occurrences (all)	1	0	
Cholestasis			
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)	
occurrences (all)	0	1	
Skin and subcutaneous tissue disorders			
Pruritus			
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)	
occurrences (all)	0	1	
Acne			
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)	
occurrences (all)	0	1	
Alopecia			
subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)	
occurrences (all)	1	0	
Decubitus Ulcer			
subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)	
occurrences (all)	1	0	
Dermal Cyst			

subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)	
occurrences (all)	0	1	
Dermatitis			
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)	
occurrences (all)	0	1	
Eczema			
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)	
occurrences (all)	0	1	
Erythema Nodosum			
subjects affected / exposed	3 / 107 (2.80%)	0 / 108 (0.00%)	
occurrences (all)	3	0	
Intertrigo			
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)	
occurrences (all)	0	1	
Psoriasis			
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)	
occurrences (all)	0	1	
Rash			
subjects affected / exposed	1 / 107 (0.93%)	1 / 108 (0.93%)	
occurrences (all)	1	1	
Urticaria			
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)	
occurrences (all)	0	1	
Renal and urinary disorders			
Pollakiuria			
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)	
occurrences (all)	0	1	
Pelvi-Ureteric Obstruction			
subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)	
occurrences (all)	1	0	
Musculoskeletal and connective tissue disorders			
Arthritis			
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)	
occurrences (all)	0	1	
Arthralgia			

subjects affected / exposed	4 / 107 (3.74%)	3 / 108 (2.78%)	
occurrences (all)	4	3	
Back Pain			
subjects affected / exposed	1 / 107 (0.93%)	4 / 108 (3.70%)	
occurrences (all)	1	4	
Greater Trochanteric Pain Syndrome			
subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)	
occurrences (all)	1	0	
Groin Pain			
subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)	
occurrences (all)	1	0	
Muscle Contracture			
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)	
occurrences (all)	0	1	
Neck Pain			
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)	
occurrences (all)	0	1	
Osteoarthritis			
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)	
occurrences (all)	0	1	
Pain in Jaw			
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)	
occurrences (all)	0	1	
Polyarthritis			
subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)	
occurrences (all)	1	0	
Rheumatic Disorder			
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)	
occurrences (all)	0	1	
Spondylitis			
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)	
occurrences (all)	0	1	
Fistula			
subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)	
occurrences (all)	1	0	
Infections and infestations			

Enteritis Infectious		
subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)
occurrences (all)	1	0
Abscess Soft Tissue		
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)
occurrences (all)	0	1
Anal Abscess		
subjects affected / exposed	2 / 107 (1.87%)	1 / 108 (0.93%)
occurrences (all)	2	1
Bronchitis		
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)
occurrences (all)	0	1
Covid-19		
subjects affected / exposed	16 / 107 (14.95%)	12 / 108 (11.11%)
occurrences (all)	16	12
Coronavirus Infection		
subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)
occurrences (all)	1	0
Conjunctivitis		
subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)
occurrences (all)	1	0
Clostridium Difficile Infection		
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)
occurrences (all)	0	1
Erythema Migrans		
subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)
occurrences (all)	1	0
Gastroenteritis		
subjects affected / exposed	4 / 107 (3.74%)	2 / 108 (1.85%)
occurrences (all)	4	2
Gastroenteritis Viral		
subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)
occurrences (all)	1	0
Gastrointestinal Infection		
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)
occurrences (all)	0	1

Herpes Zoster		
subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)
occurrences (all)	1	0
Infected Fistula		
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)
occurrences (all)	0	1
Infection		
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)
occurrences (all)	0	1
Influenza		
subjects affected / exposed	1 / 107 (0.93%)	4 / 108 (3.70%)
occurrences (all)	1	5
Lower Respiratory Tract Infection		
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)
occurrences (all)	0	1
Nasopharyngitis		
subjects affected / exposed	5 / 107 (4.67%)	3 / 108 (2.78%)
occurrences (all)	8	5
Otitis Externa		
subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)
occurrences (all)	1	0
Pharyngitis Streptococcal		
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)
occurrences (all)	0	1
Pyelitis		
subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)
occurrences (all)	1	0
Pyelonephritis		
subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)
occurrences (all)	1	0
Sinusitis		
subjects affected / exposed	0 / 107 (0.00%)	2 / 108 (1.85%)
occurrences (all)	0	2
Upper Respiratory Tract Infection		
subjects affected / exposed	0 / 107 (0.00%)	5 / 108 (4.63%)
occurrences (all)	0	5

Ureaplasma Infection			
subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)	
occurrences (all)	1	0	
Urinary Tract Infection			
subjects affected / exposed	3 / 107 (2.80%)	3 / 108 (2.78%)	
occurrences (all)	3	3	
Vulvovaginal Candidiasis			
subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)	
occurrences (all)	1	0	
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)	
occurrences (all)	0	1	
Gout			
subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)	
occurrences (all)	1	0	
Hypercholesterolaemia			
subjects affected / exposed	1 / 107 (0.93%)	1 / 108 (0.93%)	
occurrences (all)	1	1	
Hypoalbuminaemia			
subjects affected / exposed	1 / 107 (0.93%)	1 / 108 (0.93%)	
occurrences (all)	1	1	
Hypokalaemia			
subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)	
occurrences (all)	1	0	
Hypophosphataemia			
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)	
occurrences (all)	0	1	
Iron Deficiency			
subjects affected / exposed	0 / 107 (0.00%)	1 / 108 (0.93%)	
occurrences (all)	0	1	
Type 2 Diabetes Mellitus			
subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)	
occurrences (all)	1	0	
Vitamin D Deficiency			



subjects affected / exposed	1 / 107 (0.93%)	1 / 108 (0.93%)	
occurrences (all)	1	1	
Zinc Deficiency			
subjects affected / exposed	1 / 107 (0.93%)	0 / 108 (0.00%)	
occurrences (all)	1	0	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
19 July 2019	The purpose of this amendment was to include information regarding the planned primary endpoint database lock at Week 16 and the final database lock. Other clarifications and changes were made to address investigator and site questions surrounding operational elements of the study.
08 April 2020	The purpose of this amendment was to allow for self-administration of subcutaneous study intervention at Weeks 8 and 16 outside a study site (eg, at home), in cases where a study site visit is not possible under restrictions and limitations during the Coronavirus Disease-2019 (COVID-19) pandemic. Guidance on other aspects of study conduct during the COVID-19 pandemic is also included.
19 May 2020	The purpose of this amendment was to allow subcutaneous injections of study intervention at Week 8 and Week 16 to be self-administered outside a study site, in cases where a site visit is not possible.
05 August 2020	The purpose of this amendment was to increase enrollment into the study, through allowing subjects who have previously received a dose interval shortening of 90mg SC ustekinumab less than every 8 weeks and clarify ileocolonoscopy as an exploratory endpoint for subjects who agree to this procedure.

Notes:

### Interruptions (globally)

Were there any global interruptions to the trial? Yes

Date	Interruption	Restart date
26 March 2020	Enrollment was temporarily held early in the COVID-19 pandemic.	01 July 2020

Notes:

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Some exploratory endpoints including endoscopic assessments for baseline and week 16 and clinical data for 24 weeks are not reported in this summary and will be included in the manuscript.

Notes: